SOLICITATION NOTICE
66 -- Amaxa Nucleofector II Device and Nucleofector Shuttle
- Notice Date
- 9/3/2008
- Notice Type
- Presolicitation
- NAICS
- 339112
— Surgical and Medical Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-80222-MM
- Archive Date
- 10/2/2008
- Point of Contact
- Melissa P Marino, Phone: 301-402-4509, Caren N Rasmussen,, Phone: (301) 402-4509
- E-Mail Address
-
marinome@mail.nih.gov, cr214i@nih.gov
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI), Center for Cancer Research (CCR), Laboratory of Pathology plans to procure on the brand name Amaxa Nucleofector II Device, Model AAD-1001S and Nucleofector Shuttle with Amaxa, Inc.; 205 Perry Parkway, Suite 7; Gaithersburg, Maryland 20877-1416. The services herein are being procured in accordance with the simplified acquisition procedures authorized by FAR Part 13.106-1 (b) (1). The North American Industry Classification System Code is 339112 the business size standard is 500 employees. This notice is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. No faxed or emailed capability statements will be accepted. Contractor shall provide one (1) original and one (1) copy of the capability statement. Capability statements must be received in the contracting office by 1:00 PM EST, on September 17, 2008. All questions must be in writing and can be faxed or emailed to: Melissa Marino, Contract Specialist via electronic mail at marinome@mail.nih.gov or fax 301-402-4513. It is the vendors' responsibility to ensure all questions have been received in the contracting office. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, contractors must be registered and have valid certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA). Reference: NCI-80222-MM on all correspondence. JUSTIFICATION FOR OTHER THAN FULL AND OPEN COMPETITION: Part I: Background information and description of requirements: The Lung Cancer Sections purpose is to identify the molecular mechanisms regulating the critical genes and gene products in human lung cancer and animal models. The overall program and its purpose is to work on molecular and cellular biology of lung cancer and to identify potentially important drug targets in lung cancer and to develop targeted therapeutics for the prevention and treatment of cancer. The nucleofector device shall be used to evaluate and to develop drugs to observe changes in cancer cell lines following transfection of critical genes. A wide variety of lung cancer cell lines shall be investigated and the mechanism of action of various genes shall be determined. The results of these types of studies shall enable the lab to evaluate new drugs to be used in the clinical setting to aid in the prevention and possible cure of lung cancers. The Amaxa nucleofector II device and shuttle shall be used to study the role of critical genes associated with lung cancer and determine how these genes affect the development and progression of cancer in human cancer cell lines. By its novel ability to transport the genes of interest directly into the nucleus of the cells, a greater understanding of how these genes function in the human patient and how they can affect the potency of new therapies can more easily be determined. Part II: Facts and Reasons to Justify Other than Full and Open Competition: Statutory Authority Statute: This justification has been prepared under the authority of 41 U.S.C. 253 (c)(1) as set forth in 13.106-1 (b)(1).. (b) Soliciting from a single source. (1) For purchases not exceeding the simplified acquisition threshold, contracting officers may solicit from one source if the contracting officer determines that the circumstances of the contract action deem only one source reasonably available (e.g., urgency, exclusive licensing agreements, or industrial mobilization). No other requirement and/or type for supply or service will satisfy agency need. No other requirement and/or type for supply or service will satisfy agency need. Justification The Amaxa nuclefector is the only company which develops and commercialized the Nucleofector technology and is not available from any distributor in the US. The nucleofector concept uses a unique combination of parameters and solutions for transfering critical genes into primary cell and difficult to transfect cell lines with unprecedented efficiencies. The nucleofector instrument will greatly improve the quality of the experiments being performed as well as significantly increasing the number of reproducible experiments that can be performed in a given amount of time. There is no other source known to the NCI that can supply this equipment. Salient Characteristics of the Amaxa Nucleofector II Device and Nucleofector Shuttle: •Non-viral gene transfer into primary cells and hard-to-transfect cell lines. •Transfers DNA directly into cell nucleus. •Transfects 96 Well Plates of cDNA, shRNA and/or siRNA into primary cells and cell lines with transfection efficiency of 90%. •Selects specific electrical parameters which have been customized for individual cell types. •Transfects both primary cell types and individual cell lines. •Transfects from 1 individual cell type up to 96 different cell types at a time. •The Shuttle has optimized protocols to transfect selected targets at high efficiency and high cell viability into primary cells and cell lines. •Dell Latitude D520 computer, Pentium M 740 186GHz-15,0" XGA Intel Core Duo Processor 1.86 GHz with enhanced Intel SpeedStep Technology. •Input Voltage: 110 VAC /230 VAC (self regulating) •Temperature Range: +15 degrees C up to 40 degrees C (59 degreesF - 104 degrees F) •Transfections per minute: 8 - 13 Nucleofector II Device: •Interfaces: RS422, USB •Output: HV-output •Certification: EN 61010 - 1:2001 UL 61010 - 1:2001 •According to En60529: IP 22 - protection against foreign materials oProtection against dripping water up to 15 degrees Nucleofector 96-Well Shuttle: •Power supply:100-240VAC 50/60Hz 400mA •Output: 12DC, 1.2A •Only use power supply Friwo Type FW 7555M/12 •Power condition: 12DC, 20VA •Operation Temperature: 15-40 degrees C •Altitude: <2000 m above seal level
- Web Link
-
FedBizOpps Complete View
(https://www.fbo.gov/?s=opportunity&mode=form&id=6950e7c5a1610e762e75604f41c67859&tab=core&_cview=1)
- Record
- SN01658334-W 20080905/080903223431-6950e7c5a1610e762e75604f41c67859 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |